Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
Phase III Trial of Salvage Stereotatic Radiosurgery (SRS) or SRS + Hippocampalacodiant Whole Brain Radiotherapy (HA WBRT) for First or Second Distant Brain Relapse After Upfront SRS with Brian Metastasis Velocity =4 Brian Metastases/ Year
NCT Number:
NCT04588246
Phase:
III
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Brain and Nervous System
Study Objectives:
This phase III trial compares the effect of adding whole brain radiotherapy with hippocampal avoidance and memantine to stereotactic radiosurgery versus stereotactic radiosurgery alone in treating patients with cancer that has spread to the brain and come back in other areas of the brain after earlier stereotactic radiosurgery. Hippocampus avoidance during whole-brain radiation therapy decreases the amount of radiation that is delivered to the hippocampus, which is a brain structure that is important for memory. The medicine memantine is also often given with whole brain radiation therapy because it may decrease the risk of side effects of radiation on thinking and memory. Stereotactic radiosurgery delivers a high dose of radiation only to the small areas of cancer in the brain and avoids the surrounding normal brain tissue. Adding whole brain radiotherapy with hippocampal avoidance and memantine to stereotactic radiosurgery may be effective in shrinking or stabilizing cancer that has spread to the brain and returned in other areas of the brain after receiving stereotactic radiosurgery.
Study Documents
(MUSC NetID required for document access)